foxo4-dri peptide senolytic mouse study 2023 2024

foxo4-dri peptide senolytic mouse study 2023 2024 The disordered p53 transactivation domain is the target of FOXO4 and the compound foxo4-dri senolytic mouse 2023 2024

Name: foxo4-dri peptide senolytic mouse study 2023 2024 The disordered p53 transactivation domain is the target of FOXO4 and the compound foxo4-dri senolytic mouse 2023 2024
Brand: iglepidom.org
SKU: 6717436011
Price: 21.64 USD
Availability: InStock
Rating: 4.8559 (10 reviews)

foxo4 dri senolytic mouse 2023 2024 Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging: Cell Peptide targeting senescent cells restores The costs and benefits of senotherapeutics for human health The Lancet Healthy Longevity Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine Frontiers FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway

SKU: 6717436011 · From iglepidom.org

4.9

USD21.64 USD68.64

Pay in 4 interest-free payments of $5.41 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 2 - Aug 7

Description

Mutations in FOXO genes have been suggested to cause hyperglycemia and hyperlipidemia and may even increase the risk of carcinogenesis in test models

7.3.2 Functional validation of epigenetic modifications 7.3.2.1 CRISPR-based epigenetic editing CRISPR/dCas9-mediated epigenetic editing provides powerful tools to reverse or confirm EED-induced DNA methylation changes (143)